Analystreport

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $50.00 price target on the stock,

Rocket Pharmaceuticals, Inc.  (RCKT) 
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: rocketpharma.com